Application of Intravitreal Bevacizumab for Circumscribed Choroidal Hemangioma
Korean Journal of Ophthalmology
;
: 127-131, 2009.
Artículo
en Inglés
| WPRIM
| ID: wpr-180437
ABSTRACT
We report 3 cases of circumscribed choroidal hemangioma (CCH) effectively managed with intravitreal bevacizumab. One patient (case 1) who had recurrent CCH (1.6 mm in thickness) with prior laser photocoagulation was treated with intravitreal bevacizumab alone. Two patients (case 2 and 3) who had CCH (2.4 mm and 2.2 mm in thickness, respectively) with recent visual impairment were treated with bevacizumab followed by photodynamic therapy (PDT). Ophthalmic evaluations included visual acuity, ophthalmoscopic examination, fluorescein angiography, ultrasonography, and optical coherence tomography. Patients were followed up for 6-9 months. After therapy, all patients showed improved visual acuity due to complete resorption of subretinal fluid and macular edema. Ultrasonography demonstrated a reduction of the thickness of CCH in case 1 and complete regression of the lesions in case 2 and 3. No patient showed tumor recurrence. Intravitreal bevacizumab, alone or in combination therapy with PDT, may be a useful alternative for the treatment of symptomatic CCH with subretinal fluid.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Oftalmoscopía
/
Cuerpo Vítreo
/
Neoplasias de la Coroides
/
Estudios de Seguimiento
/
Inhibidores de la Angiogénesis
/
Factor A de Crecimiento Endotelial Vascular
/
Tomografía de Coherencia Óptica
/
Diagnóstico Diferencial
/
Hemangioma
/
Inyecciones
Tipo de estudio:
Estudio diagnóstico
/
Estudio observacional
/
Estudio pronóstico
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Korean Journal of Ophthalmology
Año:
2009
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS